COMMUNIQUÉS West-GlobeNewswire

Pixium Vision : Information relative au nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2019
01/02/2019
Information relative au nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2019 Paris, le 1 er février 2019 – 18 :00 CET - Pixium Vision (FR0011950641 - PIX), société bioélectronique [...]
Nicox: Number of voting rights as of january 31, 2019
01/02/2019
Nicox SA Société anonyme with a registered capital of € 29,718,920 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On February 1, 2019, MONTHLY PUBLICATION OF THE [...]
Nicox : Nombre de droits de vote au 31 janvier 2019
01/02/2019
Nicox SA Société anonyme au capital de 29 718 920 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 1er février 2019, PUBLICATION MENSUELLE DU NOMBRE D' [...]
Title21 Health Solutions Is a ‘Great Place to Work’®
01/02/2019
Cellular Therapy and Enterprise Quality Management Software Company is Recognized as Having an Outstanding Culture by Great Place to Work® PLEASANTON, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Title21 Health Solutions [...]
BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study
01/02/2019
MORRISTOWN, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced the publication of a paper in Clinical Infectious Disease—a journal of the Infectious Disease Society of America entitled, Low [...]
Active Biotech has received an indicative bid for the property in Lund - the Board is positive
01/02/2019
As previously reported, Active Biotech's property Forskaren 1 in Lund has been on sale for a period of time. Active Biotech has now received an indicative, non-binding bid for the property, amounting to SEK 275 million [...]
Typenex® Medical Awarded National MAGNET GROUP Contract
01/02/2019
Gives Members Access to Full Portfolio of Patient Identification Products CHICAGO, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Typenex Medical , an industry leader in Healthcare, announced it has been awarded the MAGNET GROUP GPO [...]
Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement
01/02/2019
CRANBURY, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it closed on the final tranche (of four) of its $20.0 million private placement of common [...]
Former Assistant U.S. Attorney Joins Phoenix Life Sciences International as Company’s Vice President of Regulatory Affairs
01/02/2019
DENVER, CO, Feb. 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that [...]
HMS to Report Fourth Quarter 2018 Financial Results on February 22, 2019
01/02/2019
IRVING, Texas, Feb. 01, 2019 (GLOBE NEWSWIRE) -- HMS Holdings Corp. (Nasdaq: HMSY) today announced it will report financial and operating results for the fourth quarter and year ended December 31, 2018 at 7:30 am CT / 8 [...]
Milestone Scientific Announces Pricing of $2.0 Million Offering of Common Stock and Warrants
01/02/2019
LIVINGSTON, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced today the [...]
Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on Friday, March 1, 2019
01/02/2019
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results [...]
OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer
01/02/2019
MIAMI, Feb. 01, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s point-of-care Sangia Total Prostate Specific Antigen ( [...]
AroCell launches new website
01/02/2019
Today AroCell is launching its new website. The goal with the new website is to facilitate for our customers, business partner, and investors to find relevant information about AroCell. The website (arocell.com) informs [...]
Auris Medical Announces Full Repayment of Hercules Loan Facility
01/02/2019
Zug, Switzerland, February 1, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous [...]
Dentsply Sirona to Host Fourth Quarter and Full Year 2018 Conference Call on March 1st
01/02/2019
YORK, Pa., Feb. 01, 2019 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (NASDAQ:XRAY), The Dental Solutions Company™, today announced that the Company will host an investor conference call and live webcast on Friday, March 1 [...]
AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
01/02/2019
CAMBRIDGE, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and investor presentation [...]
Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction
01/02/2019
INDIANAPOLIS and STAMFORD, CT, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) today announced the expiration of the waiting period [...]
Abeona Therapeutics présentera de nouvelles données de soutien pour les nouvelles thérapies géniques au WORLDSymposium™
01/02/2019
NEW YORK et CLEVELAND, 01 févr. 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq : ABEO), société biopharmaceutique de stade clinique de premier plan spécialisée dans le développement de nouvelles thérapies [...]

Pages